Overview |
bsm-52317r |
EGFR Recombinant Antibody |
WB, IHC-P, IF(IHC-P), IF(ICC), IP |
Human, Mouse, Rat |
Specifications |
Unconjugated |
Rabbit |
Recombinant Human protein. |
Monoclonal |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS (pH 7.4), 1% BSA, 0.02% Proclin 300, and 50% Glycerol |
Store at 4°C for up to 2 weeks. For long term storage, store at -20°C in small aliquots to prevent freeze-thaw cycles. |
Target |
1956 |
P00533 |
Secreted, Cell membrane |
Epidermal growth factor receptor; Proto-oncogene c-ErbB-1; Receptor tyrosine-protein kinase erbB-1; EGFR; ERBB; HER1; mENA; ERBB1; PIG61; NISBD2 |
Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses. Known ligands include EGF, TGFA/TGF-alpha, amphiregulin, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF. Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascades including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules. May also activate the NF-kappa-B signaling cascade. Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling. Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin. Isoform 2 may act as an antagonist of EGF action. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |
IF(IHC-P) |
1:50-200 |
IF(ICC) |
1:50-200 |
IP |
1-2ug |